CSL partners with Alentis for lixudebart in rare kidney and liver diseases
CSL Limited (ASX: CSL) has entered into a global partnership with Alentis Therapeutics to co-develop and co-promote the drug lixudebart, which is being developed for rare kidney and liver conditions. The deal includes an upfront payment of $355 million from CSL to Alentis, along with potential additional payments tied to development milestones. Lixudebart has shown promise in early trials targeting diseases such as autosomal dominant polycystic kidney disease (ADPKD) and non-alcoholic steatohepatitis (NASH). The collaboration aims to accelerate the drug’s clinical progress and commercialization. CSL, a global leader in biotechnology, is expanding its portfolio into rare diseases through this strategic partnership. The deal highlights growing interest among pharmaceutical companies in addressing unmet medical needs for rare conditions with high-potential therapies.
Tickers: $CSLLY